Pinned straw:
I've been reviewing Microba's quarterlies and rewatching the recent webinar. I've noticed they haven't been saying much about what's happening with testing sales internationally and that's part of what makes the highlighted metrics seem inconsistent. I imagine that there's some trial and error going on.
Reading between the lines of Luke's comments about maintaining focus and speed, and avoiding 'distractions disguised as opportunities', they have more options than they have staff to handle them. That's a good problem to have provided they do remain focused and grow convincingly.
Australian testing sales have been growing well. He's confident that the pattern should repeat in the UK - feedback from the early access testing with Invivo suggest clinicians are liking the more detailed results. I think they sent in extra sales staff to help clinicians transition to the new product. That will become evident in the next few quarters. And then he's dropping hints about progress towards reimbursement arrangements in the US.
As he says, this is a growth company. The set up, the team, the international partners, the avenues to grow (as listed in the projects list I posted) are all there. The projected market sizes are in the billions. I suppose most sensible people will wait to see a longer period of sales growth, but I'm a sucker for a good story.
Regarding the therapeutics projects, the allergies project with International Flavors and Fragrances in particular caught my attention. IFF are truly international and a long established food science, health science and fragrance company (they went public in 1960). They have the ability to formulate, produce and distribute at scale.